Business Context and Reporting Period
This Form 8-K is a current report filed by Catalyst Biosciences, Inc. (trading symbol: CBIO) on July 14, 2021. The filing discloses significant changes in executive leadership, specifically the promotion of Grant Blouse to Chief Scientific Officer and the planned retirement of Howard Levy, the Chief Medical Officer.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on personnel changes and the terms of an employment agreement.
Material Changes
Executive Promotion
Grant Blouse was promoted to Chief Scientific Officer effective July 14, 2021. He previously served as Senior Vice President, Translational Research. His new compensation package includes:
- Base Salary: $414,000 annually.
- Performance Bonus: Eligible for up to 40% of base salary.
- Severance (Standard Termination): 9 months of base salary, accelerated vesting of options for that period, and COBRA premium coverage.
- Severance (Change in Control): 12 months of 100% base salary plus 100% of maximum bonus, 100% accelerated vesting of unvested options, and COBRA coverage.
Executive Retirement
Howard Levy, Chief Medical Officer, announced his retirement effective August 15, 2021. The filing states this decision was not due to any disagreement with the Company. Dr. Levy will join the Clinical Advisory Board and provide consulting services on hemophilia programs.
Guidance, Outlook, and Risks
The filing contains no financial guidance, market outlook, or discussion of general business risks. The primary contingency noted is the transition of leadership roles within the scientific and medical divisions of the company.
Investor Verification Checklist
- Verify the impact of the Chief Medical Officer's departure on ongoing clinical trials, particularly in hemophilia programs.
- Review the attached employment agreements (Exhibits 10.1 and 10.2) for specific definitions of "cause" and "constructive termination."
- Monitor future filings for the appointment of a successor to the Chief Medical Officer role.
- Confirm the status of the Clinical Advisory Board's role in the company's strategic direction.